Interim analysis of cytarabine (ara-C) and cladribine (2-CDA) combination therapy in acute myeloid leukemia (AML).

被引：0
|
作者：
Radomski, KM
Gandhi, V
Srivastava, DK
Razzouk, BI
Behm, FG
Plunkett, W
Pui, CH
Rubnitz, JE
Ribeiro, RC
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1411
引用
收藏
页码：327A / 327A
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, B. Nebiyou
    Jabbour, Elias
    Ravandi, Farhad
    Yang, Hui
    Borthakur, Gautam
    Kadia, Tapan
    Cortes, Jorge
    Faderl, Stefan
    Konopleva, Marina
    Pierce, Sherry
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Thomas, Deborah
    Newsome, Willie
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 436 - 436
  • [42] Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).
    Beran, H
    Giles, FJ
    Cortes, JE
    Thomas, DA
    Koller, C
    O'Brien, SM
    Keating, MJ
    Freireich, E
    Kantarjian, HM
    Estey, E
    BLOOD, 1999, 94 (10) : 226B - 226B
  • [43] Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)
    Erba, H. P.
    Rizzieri, D. A.
    O'Donnell, M. R.
    Lundberg, A. S.
    Ajami, A. M.
    Rampersad, A. D.
    Capizzi, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] INVIVO GROWTH AND ARA-C PHARMACOLOGICAL DETERMINANTS OF CLINICAL-RESPONSE IN ACUTE MYELOID-LEUKEMIA (AML)
    KARP, JE
    DONEHOWER, RC
    DOLE, GB
    ENTERLINE, J
    BURKE, PJ
    CELL AND TISSUE KINETICS, 1988, 21 (01): : 61 - 62
  • [45] Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia
    Crews, KR
    Gandhi, V
    Srivastava, DK
    Razzouk, BI
    Tong, X
    Behm, FG
    Plunkett, W
    Raimondi, SC
    Pui, CH
    Rubnitz, JE
    Stewart, CF
    Ribeiro, RC
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4217 - 4224
  • [46] PERTURBED CELL-GROWTH AND ARA-C PHARMACOLOGY IN ACUTE MYELOID-LEUKEMIA (AML) AT DIAGNOSIS AND AT RELAPSE
    KARP, JE
    DONEHOWER, RC
    DOLE, GB
    BURKE, PJ
    CELL AND TISSUE KINETICS, 1987, 20 (02): : 244 - 244
  • [47] Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose ara-C therapy and conventional consolidation therapy (JALSG AML 201 study).
    Miyawaki, Shuichi
    Ohtake, Shigeki
    Fujisawa, Shin
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Miyamura, Koichi
    Nishimura, Miki
    Miyazaki, Yasushi
    Nishii, Kazuhiro
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2006, 108 (11) : 567A - 567A
  • [48] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).
    Zeidan, Amer
    Tan, Wei
    Wilding, Gregory
    Ford, LaurieAnn
    Hahn, Theresa
    Smiley, Shannon
    Battiwalla, Minoo
    McCarthy, Philip L.
    Wang, Eunice S.
    Wetzler, Meir
    BLOOD, 2008, 112 (11) : 350 - 351
  • [50] HIGH-DOSE CYTARABINE (ARA-C) TREATMENT FOR THERAPY-RESISTENT ACUTE MYELOID-LEUKEMIA - EFFECT - SIDE-EFFECT
    MEUSERS, P
    MENKEN, U
    HEIDEMANN, H
    BRITTINGER, G
    ONKOLOGIE, 1983, 6 (05): : 224 - 224
12345